| Ezetimibe (n  = 17) | Atorvastatin (n  = 16) | p-value |
---|---|---|---|
Age (years) | 64.2 ± 9.8 | 65.0 ± 8.0 | 0.81 |
Sex, male (%) | 7 (41.2%) | 8 (50.0%) | 0.73 |
Body mass index (kg/m2) | 22.5 ± 2.4 | 23.3 ± 3.5 | 0.45 |
Hypertension (%) | 9 (56.3%) | 9 (52.9%) | 1.00 |
Current smoking (%) | 4 (23.5%) | 4 (25.0%) | 1.00 |
Hemoglobin A1c (%) | 7.3 ± 1.1 | 6.9 ± 0.6 | 0.18 |
Fasting plasma glucose (mg/dL) | 135.8 ± 21.5 | 131.4 ± 21.4 | 0.57 |
Duration of diabetes (yeas) | 13.6 ± 8.1 | 11.9 ± 9.3 | 0.58 |
Total cholesterol (mg/dL) | 237.5 ± 25.8 | 226.6 ± 29.5 | 0.27 |
LDL cholesterol (ng/mL) | 148.8 ± 22.1 | 135.6 ± 19.7 | 0.08 |
HDL cholesterol (mg/dL) | 57.0 ± 11.3 | 54.9 ± 19.0 | 0.71 |
Triglyceride (mg/dL) | 112.0 (100.0–192.5) | 134.5 (76.3–229.3) | 0.83 |
Anti-diabetic medicines | - | - | - |
 Sulfonylureas (%) | 2 (11.8%) | 5 (31.5%) | 0.23 |
 Metformin (%) | 5 (29.4%) | 4 (25.0%) | 1.00 |
 Alpha-glucosidase inhibitor (%) | 5 (29.4%) | 6 (37.5%) | 0.72 |
 Thiazolidinedione (%) | 1 (5.9%) | 2 (12.5%) | 0.60 |
 Glinide (%) | 0 (0%) | 1 (6.3%) | 0.49 |
 DPP-4 inhibitor (%) | 1 (5.9%) | 2 (12.5%) | 0.60 |
 Insulin (%) | 8 (47.1%) | 3 (18.8%) | 0.14 |
Any anti-diabetic medications (%) | 14 (82.3%) | 14 (87.5%) | 0.53 |
LnRHI | 0.471 ± 0.157 | 0.552 ± 0.084 | 0.076 |